Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:
We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).
Best Biotech Stocks To Invest In Right Now: Aclaris Therapeutics, Inc.(ACRS)
- [By Peter Graham]
Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.
- [By Chris Lange]
Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.
Best Biotech Stocks To Invest In Right Now: Dave & Buster's Entertainment, Inc.(PLAY)
- [By Lisa Levin]
Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) shares were also up, gaining 17 percent to $56.39 after the company reported stronger-than-expected results for its third quarter and boosted its full year net income guidance.
Best Biotech Stocks To Invest In Right Now: Orbital ATK, Inc.(OA)
- [By Rich Smith]
Orbital ATK (NYSE:OA) occupies a charmed space in the U.S. market for putting satellites in, er, space.
At one end of the space launch continuum, you have United Launch Alliance, whose Delta IV Heavy launch vehicle, developed by Boeing (NYSE:BA), can put a payload massing in excess of 28 tonsinto orbit in a single launch — at a cost of $350 million.At the other end, new space start-ups like Vector Space are promising to launch a new generation of small satellites into low-earth orbit for prices as little as $2 million a shot. But what about the middle?
- [By Rich Smith]
While Trump’s nuclear tweet appears to have taken some folks off guard, the fact is that the U.S. has been planning a major upgrade and refurbishmentof its nuclear arsenal for quite some time — since at least the early years of the second Obama administration, in fact. As far back as three years ago, we were writing about a U.S. Air Force effort to begin upgrading the nation’s aging fleet of Minuteman III intercontinental ballistic missiles — a contract that Aerojet Rocketdyne (NYSE:AJRD), among others, is counting on to juice its rocket revenues. Rival rocket scientist Orbital ATK (NYSE:OA) is bidding on the same contract, and whether it’s Aerojet or Orbital that eventually ends up winning this piece of the nuclear rearmament project, there should be money aplenty to go around.
- [By Rich Smith]
Now consider that as of the last report, Americans owned 265 million guns — but fewer than 1 million silencers. That’s a huge market that American Outdoor Brands and Sturm, Ruger would love to sell into. Easing restrictions on silencer sales could have follow-on effects, too. Granting easier access to suppressors could reduce noise complaints at open-air shooting ranges, making it easier for such businesses to open, which would attract more customers, resulting in more ammunition being used, resulting in more ammunition being sold, resulting in more sales (and profits) for ammo makers such as Olin Corp (NYSE:OLN), Vista Outdoor (NYSE:VSTO), and Orbital ATK (NYSE:OA).